ArticleEuropean journal of case reports in internal medicine2025
Tuberculous Meningitis and Hemophagocytic Lymphohistiocytosis in a Patient on Adalimumab: Diagnostic Challenges in the Setting of Suspected Non-Tuberculous Mycobacteria Co-Infection.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumour necrosis factor-alpha (TNF-alpha) inhibitors increase susceptibility to granulomatous infections, including both Case report: A 65-year-old man on long-term adalimumab for psoriasis presented with prolonged fever, hepatosplenomegaly, cytopenia and elevated inflammatory markers. Bone marrow aspiration revealed hemophagocytosis and liver and bone marrow biopsy revealed granulomatous inflammation. Polymerase chain reaction (PCR) testing of bronchoalveolar lavage (BAL) fluid identified MAC, supporting a diagnosis of disseminated MAC-associated HLH. The patient responded to triple MAC therapy (azithromycin, ethambutol, rifampicin), intravenous immunoglobulin and low-dose corticosteroids, with rapid clinical improvement. Three months later, he was readmitted with fever and altered mental status. Brain magnetic resonance imaging showed meningeal thickening. Lumbar puncture revealed cerebrospinal fluid pleocytosis, hypoglycorrhachia and elevated protein. PCR detected MTB complex deoxyribonucleic acid and a rifampicin resistance gene, prompting the initiation of a four-drug antituberculosis regimen (isoniazid, pyrazinamide, levofloxacin, ethambutol) and high-dose dexamethasone. The patient improved and was discharged after a month of hospitalization, remaining clinically stable at 1-year follow-up. Conclusion: This case highlights the risk of sequential or overlapping MAC and MTB infections in patients receiving TNF-alpha inhibitors, the potential for HLH as a serious complication, and the diagnostic value and limitations of BAL PCR testing. Vigilant screening and multidisciplinary management are essential in such high-risk populations. LEARNING POINTS: The increased risk of opportunistic infections associated with long-term tumour necrosis factor-alpha inhibitor use necessitates ongoing infection screening.Hemophagocytic lymphohistiocytosis triggered by mycobacterial infections requires prompt recognition and targeted treatment.Polymerase chain reaction results should be interpreted with caution in complex clinical scenarios, as deoxyribonucleic acid detection may indicate colonization rather than active infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.